Home » Pipeline
Pipeline
February 12, 2018
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Fibrocell Science | FCX-013 | moderate to severe localized scleroderma | IND submitted to the FDA |
| Daiichi Sankyo | U3-1402 | metastatic or unresectable epidermal growth factor receptor-mutated non-small cell lung cancer | Phase I trials initiated enrolling 60 subjects globally |
| Palatin Technologies | PL-8177 | ulcerative colitis and other inflammatory bowel diseases | Phase I trials initiated enrolling 52 subjects |
| Phosplatin Therapeutics | PT-112 | relapsed or refractory multiple myeloma | Phase I/II trials initiated |
| Gemphire | gemcabene | pediatric nonalcoholic fatty liver disease | Phase IIa trials initiated enrolling 40 adolescent children between the ages of 12 and 17 |
| OncBioMune Pharmaceuticals | ProscaVax | advanced prostate cancer | Phase II trials initiated |
| Xcovery | ensartinib (X-396) | advanced malignant melanoma harboring alterations in ALK | Phase II trials initiated |
| Endo International | collagenase clostridium histolyticum | cellulite | Phase III trials initiated enrolling 840 women in the U.S. |
| Pharma Two B | P2B001 | early Parkinson's disease | Phase III trials initiated enrolling 525 subjects |
| Tessa Therapeutics | T cell immunotherapy | nasopharyngeal cancer | Phase III trials initiated enrolling 35 subjects |
| GlaxoSmithKline | Bexsero | meningitis B vaccine | Breakthrough Therapy designation granted by the FDA |
| Sage Therapeutics | SAGE-217 | major depressive disorder | Breakthrough Therapy designation granted by the FDA |
| Zogenix | ZX008 (low-dose fenfluramine) | seizures associated with Dravet syndrome | Breakthrough Therapy designation granted by the FDA |
| MeiraGTx | AAV2/8-hCARp.hCNGB3 (A002) | achromatopsia due to mutations in the CNGB3 gene | Rare Pediatric Disease designation granted by the FDA |
| Adhesys Medical | VIVO | surgical sealant | Expedited Access Pathway designation granted by the FDA |
| Alnylam Pharmaceuticals | patisiran | hereditary ATTR amyloidosis | NDA accepted and Priority Review granted by the FDA |
| Allergan | Avycaz (ceftazidime and avibactam) | hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia | Expanded use approved by the FDA |
| Ferring Pharmaceuticals | Zomacton (somatropin) | human growth hormone deficiency | FDA approved |
